Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Cash & Equivalents (2016 - 2025)

Cytokinetics (CYTK) has disclosed Cash & Equivalents for 16 consecutive years, with $122.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents changed N/A to $122.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $122.5 million, a N/A change, with the full-year FY2025 number at $122.5 million, changed N/A from a year prior.
  • Cash & Equivalents was $122.5 million for Q4 2025 at Cytokinetics, up from $47.3 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $190.5 million in Q2 2024 to a low of $37.2 million in Q2 2021.
  • A 5-year average of $95.9 million and a median of $101.6 million in 2023 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: crashed 54.9% in 2021, then soared 176.06% in 2024.
  • Cytokinetics' Cash & Equivalents stood at $112.7 million in 2021, then tumbled by 40.37% to $67.2 million in 2022, then soared by 68.79% to $113.4 million in 2023, then tumbled by 58.32% to $47.3 million in 2024, then surged by 159.23% to $122.5 million in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Cash & Equivalents are $122.5 million (Q4 2025), $47.3 million (Q3 2024), and $190.5 million (Q2 2024).